Quick answer
Chronic hepatitis B has been managed with nucleos(t)ide analogues for thirty years: they suppress the virus but rarely clear it, so patients stay on treatment indefinitely. Bepirovirsen, an antisense oligonucleotide that reduces viral RNA and antigen production, is the first drug of its class to complete a phase III trial. Led globally by Nanfang Hospital's Hou Jinlin, B-Well reported functional cure in 19% of patients with baseline HBsAg ≤3000 IU/mL — and up to 61% in Chinese subgroups with lower antigen levels [1][2][4].
Key takeaways
- Global, randomised, double-blind, placebo-controlled trial across 29 countries with more than 1,800 patients [1][3].
- Bepirovirsen added to standard nucleos(t)ide therapy versus placebo [1].
- Functional cure 19% in the HBsAg ≤3000 IU/mL population [1][3].
- Chinese subgroup: 35%, 44% and 61% across progressively lower HBsAg strata [4].
- Published in NEJM on 28 May 2026 and presented at EASL the same day [2][3].
What functional cure means
Functional cure in hepatitis B means sustained loss of HBsAg and undetectable HBV DNA after stopping treatment — the virus is not eradicated from the liver, but it stops causing disease and the patient no longer needs daily antivirals. It is the accepted goal of curative research, and until now only a small minority achieved it spontaneously or with interferon [1][3].
Bepirovirsen works differently from nucleos(t)ides: it is a short strand of chemically modified RNA that binds viral transcripts and recruits RNase H to destroy them, cutting the production of HBsAg and other viral proteins. Lower antigen load is thought to let the immune system re-engage [1][3].
Reading the numbers
The 19% figure applies to patients with HBsAg up to 3000 IU/mL, a broader population than earlier studies that focused on low-antigen patients. The Chinese subgroup analysis showed a clear gradient: as baseline HBsAg fell, cure rates rose from 35% to 44% to 61%. That gradient matters clinically, because it identifies who is most likely to benefit [4].
Eighty-one per cent of patients in the primary population were not cured, and the trial's follow-up after stopping treatment is still relatively short — late relapses occur in hepatitis B. Safety data, including injection-site reactions and liver enzyme flares, need to be weighed against benefit. And the drug is expensive; Japan approved it in August 2026, and Chinese approval and reimbursement are separate questions [1][4][5].
The condition in context: hepatitis B
Chronic hepatitis B is a major cause of cirrhosis and liver cancer, especially in East Asia.
| Region | What the data shows | Source |
|---|---|---|
| Worldwide | About 250 million people have chronic hepatitis B [3][5]. | Guangzhou Daily / ScienceNet [3][5] |
| China | More than 75 million people are infected [3][5]. | Guangzhou Daily [3] |
| Treatment gap | Nucleos(t)ides suppress but rarely cure, requiring lifelong therapy [1][3]. | Nanfang Daily [1] |
Because lifelong therapy is costly and does not eliminate liver-cancer risk, a finite-course cure has been the field's central goal [1].
Why it matters
| Potential | What the report suggests | Source |
|---|---|---|
| Finite course | 24 weeks of treatment produced durable functional cure in a subset [1][4]. | [1][4] |
| Selection | Lower baseline HBsAg predicts much higher cure rates [4]. | [4] |
| Caution | Most patients not cured; durability still under follow-up [2]. | [2] |
Availability and limits
- This is an editorial summary of the publication and reports, not medical advice [1][2].
- Bepirovirsen is approved in Japan (August 2026); Chinese approval status differs [4].
- Functional cure rates depend strongly on baseline HBsAg [4].
- Long-term durability after treatment cessation needs further follow-up [2].
- Cost and reimbursement are unresolved [5].
What to ask before booking
| Question | Why it matters |
|---|---|
| What is my baseline HBsAg level? | It predicts the chance of functional cure [4]. |
| Am I eligible for a clinical programme or only standard therapy? | Access depends on approval and trials [4]. |
| Which department handles foreign patients, and in what language? | Nanfang Hospital is a working hospital we do not book; confirm international-department coordination and language support. |
| How will relapses after stopping be monitored? | Late relapse is a known risk in hepatitis B [1]. |
Questions patients ask
What is bepirovirsen?
An antisense oligonucleotide that reduces hepatitis B viral RNA and antigen production, given by injection alongside nucleos(t)ide therapy [1][3].
What did B-Well show?
Functional cure in 19% of patients with baseline HBsAg ≤3000 IU/mL, versus placebo plus standard therapy, across 29 countries and more than 1,800 patients [1][3].
What about Chinese patients?
Subgroup cure rates rose from 35% to 44% to 61% as baseline HBsAg fell [4].
Is it approved?
Japan approved it in August 2026; China's regulatory and reimbursement decisions are separate [4].
Is this relevant to international patients?
It is useful context for hepatitis B care in China. Nanfang Hospital is a working hospital we do not book — contact its international department directly [1].